title: Improvement in lung cancer outcomes with targeted therapies: an update for family physicians.
abstract: In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and in providing emotional support. Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more intensive and interactive collaboration between specialists and family physicians in the management of all phases of cancer care.
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR). christian.rolfo@uza.be.
authors.forename: Christian
authors.initials: C
authors.lastname: Rolfo
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Francesco
authors.initials: F
authors.lastname: Passiglia
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Marcin
authors.initials: M
authors.lastname: Ostrowski
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Lúcia
authors.initials: L
authors.lastname: Farracho
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Tereza
authors.initials: T
authors.lastname: Ondøichová
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Ana
authors.initials: A
authors.lastname: Dolcan
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Marta
authors.initials: M
authors.lastname: Castiglia
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Roy
authors.initials: R
authors.lastname: Remmen
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Papadimitriou
authors.affiliation: From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
authors.forename: Patrick
authors.initials: P
authors.lastname: Pauwels
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases
keywords: Cancer; Drug Therapy; Lung Cancer; Medical Oncology; Non-Small-Cell Lung Cancer; Tyrosine Kinase